Skip to main content
Premium Trial:

Request an Annual Quote

Vela Dx HCV Assay Approved in Australia

NEW YORK (GenomeWeb) – Vela Diagnostics announced this week that its next-generation sequencing-based hepatitis C genotyping assay has been approved for diagnostic use by Australian regulators.

The Sentosa SQ HCV genotyping assay covers clinically relevant regions of NS3, NS5A, and NS5B and detects genotypes 1 through 6, as well as subtypes 1a and 1b, according to the company. It runs on the company's highly automated Sentosa NGS platform.

Singapore-based Vela currently offers a CE-marked Sentosa-based test for colorectal cancer and said that it expects to launch a test for HIV next month.